Cystic fibrosis transmembrane regulator correctors and potentiators.
about
New and emerging targeted therapies for cystic fibrosisNeuronal and Cardiovascular Potassium Channels as Therapeutic Drug Targets: Promise and PitfallsCorrection of chloride transport and mislocalization of CFTR protein by vardenafil in the gastrointestinal tract of cystic fibrosis miceRibosomal Stalk Protein Silencing Partially Corrects the ΔF508-CFTR Functional Expression DefectMechanistic Approaches to Improve Correction of the Most Common Disease-Causing Mutation in Cystic FibrosisCFTR interacts with ZO-1 to regulate tight junction assembly and epithelial differentiation through the ZONAB pathway.Cystic fibrosis transmembrane conductance regulator chloride channel blockers: Pharmacological, biophysical and physiological relevance.Targeted proteomic quantitation of the absolute expression and turnover of cystic fibrosis transmembrane conductance regulator in the apical plasma membrane.The intrinsic and extrinsic effects of N-linked glycans on glycoproteostasis.Targeting protein-protein interactions to rescue Δf508-cftr: a novel corrector approach to treat cystic fibrosis.Improvement of chloride transport defect by gonadotropin-releasing hormone (GnRH) in cystic fibrosis epithelial cells.PharmGKB summary: very important pharmacogene information for CFTRA stable human-cell system overexpressing cystic fibrosis transmembrane conductance regulator recombinant protein at the cell surfaceInteraction non grata between CFTR's correctors and potentiatorsF508del-cystic fibrosis transmembrane regulator correctors for treatment of cystic fibrosis: a patent review.Some gating potentiators, including VX-770, diminish ΔF508-CFTR functional expression.Potentiators of Defective ΔF508-CFTR Gating that Do Not Interfere with Corrector Action.Improved fluorescence assays to measure the defects associated with F508del-CFTR allow identification of new active compounds.A synonymous codon change alters the drug sensitivity of ΔF508 cystic fibrosis transmembrane conductance regulator.Non-native Conformers of Cystic Fibrosis Transmembrane Conductance Regulator NBD1 Are Recognized by Hsp27 and Conjugated to SUMO-2 for Degradation.Restoration of NBD1 thermal stability is necessary and sufficient to correct ∆F508 CFTR folding and assemblyCombination therapy with cystic fibrosis transmembrane conductance regulator modulators augment the airway functional microanatomy.Pharmacological rescue of trafficking-impaired ATP-sensitive potassium channels.Therapeutics based on stop codon readthrough.Defective CFTR- β-catenin interaction promotes NF-κB nuclear translocation and intestinal inflammation in cystic fibrosis.The cystic fibrosis of exocrine pancreasThe safety dance: biophysics of membrane protein folding and misfolding in a cellular contextPersonalized medicine for cystic fibrosis: establishing human model systems.The need for new approaches in CNS drug discovery: Why drugs have failed, and what can be done to improve outcomes.Phenylhydrazones as Correctors of a Mutant Cystic Fibrosis Transmembrane Conductance Regulator.Efficacy of lumacaftor-ivacaftor for the treatment of cystic fibrosis patients homozygous for the F508del-CFTR mutation.New Therapeutic Approaches to Modulate and Correct Cystic Fibrosis Transmembrane Conductance Regulator.Finding new drugs to enhance anion secretion in cystic fibrosis: Toward suitable systems for better drug screening. Report on the pre-conference meeting to the 12th ECFS Basic Science Conference, Albufeira, 25-28 March 2015.Trafficking and function of the cystic fibrosis transmembrane conductance regulator: a complex network of posttranslational modifications.Individualized medicine using intestinal responses to CFTR potentiators and correctors.Influence of Pathogenic Mutations on the Energetics of Translocon-Mediated Bilayer Integration of Transmembrane Helices.Rescuing ΔF508 CFTR with trimethylangelicin, a dual-acting corrector and potentiator.Pharmacoperones for Misfolded Gonadotropin Receptors.An Official American Thoracic Society Workshop Report: Translational Research in Rare Respiratory Diseases.A common mechanism for CFTR potentiators.
P2860
Q26749278-A1BA8DE3-3DDF-48EE-9963-036D1B1ECF62Q26798018-F42042F4-8237-4480-A519-E8FB390A1C51Q27303954-2D5770A5-EDB9-44B8-9D70-29B9457B555BQ28551966-2D530085-6C6C-4B2D-8C1F-5B6408341FCBQ28552337-6DAF244F-34DE-42A7-8B2E-CDF0717182CFQ34339107-0E2330C7-96F8-43C4-971A-DF9C0070D3EBQ34408604-1CBAF8B3-42E4-479B-8E1B-44673DA7B2F6Q34488617-CC88D7B5-0AE1-4F4B-92B8-3D267F7E394AQ34512555-B967F643-4BCB-4B42-9A1C-A5F7FC078072Q34975372-412C5B65-B743-4902-8B94-23D89ED9A1ADQ35106485-7D36C4F1-113B-4C8C-B585-CC4BC1FB5D11Q35108743-4ADF8710-1012-4CF6-AABE-31B1C461420EQ35514729-3EDB9278-529A-4A31-896D-C301646A103CQ35561343-FE36F03B-BE07-4C6D-800C-0EC953CC1EACQ35630919-2A1D229B-9549-4B67-BA7C-07466881849CQ35743348-B1DAC836-29B1-4E3F-8A84-896655A0473FQ36077743-A4F8B1FB-719C-412D-A6D8-3440F0C81F2CQ36251047-0D8AD3C2-32E5-40CF-95F4-8718B7745FB0Q36385376-E602ED3B-DBF9-4667-A162-CBDE92E22CD8Q36489351-D995141C-8C77-4261-9996-5A2D5417DC79Q36591437-1882A75E-1EE5-4CD5-A8C7-43EE2EE4004CQ36976621-96301E1C-CF47-407B-AACF-6020993742C5Q37409971-69EBC3E4-8DC5-40B0-9114-96616B1EE8B7Q37638359-5D3ED794-7F47-4D3F-A47E-E93006FD0C79Q37665560-631D188E-11D1-437B-9FC3-9F4A1B551520Q38103532-42E8F63E-54B1-43A5-A156-AF2704F7FCD7Q38270911-2D330D10-8FA9-4BA8-B297-3A610EC6F684Q38579957-A7558D1D-F966-4388-B514-CC78A95D7620Q38775856-6F175C91-D6E1-4076-B536-E07AA3A2F65FQ38809280-0559FEBF-52D5-41B2-9CE3-E2DFD9E0D703Q38835405-559A3102-8762-460B-8011-7D92846194A0Q38836754-BA8D8DAF-7B58-4389-B598-10B9551BEF79Q38910094-102BE0FC-1087-49FA-853E-FEE344CE410BQ38913048-A1F3783F-FAC2-4A59-88F2-8CF4ABE338A7Q38962735-381F6A0F-1AFA-4CBD-BDB6-055962B172FEQ43190054-1A3C0D44-AE02-4274-8B6F-77D277CBE204Q44455766-4D9F922C-530F-47A5-B0F5-E3CDAAE997AAQ47635965-7DD010E9-4615-46B5-8F21-FE2729AFBF2FQ47815265-A4BF04E6-A874-45C3-98A8-9314D2ACF0E0Q48111581-CB3A3030-CD56-4A4F-9DFB-7B639D4D6DFE
P2860
Cystic fibrosis transmembrane regulator correctors and potentiators.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Cystic fibrosis transmembrane regulator correctors and potentiators.
@en
type
label
Cystic fibrosis transmembrane regulator correctors and potentiators.
@en
prefLabel
Cystic fibrosis transmembrane regulator correctors and potentiators.
@en
P2860
P1476
Cystic fibrosis transmembrane regulator correctors and potentiators.
@en
P2093
Alan S Verkman
Steven M Rowe
P2860
P356
10.1101/CSHPERSPECT.A009761
P577
2013-07-01T00:00:00Z